For research use only. Not for therapeutic Use.
PF-07054894（Cat No.:I042298）is a selective small molecule inhibitor developed by Pfizer, targeting the androgen receptor (AR) in androgen receptor-driven cancers, such as prostate cancer. The compound works by binding to the androgen receptor and preventing its activation, thereby blocking the signaling pathways that promote tumor growth and survival. PF-07054894 is designed to overcome resistance mechanisms seen with other AR-targeting therapies, providing a potential new option for treating castration-resistant prostate cancer (CRPC). Preclinical studies have demonstrated its efficacy in reducing tumor growth, making it a promising candidate for clinical development in oncology.
| Catalog Number | I042298 |
| CAS Number | 2413693-96-4 |
| Synonyms | 4-[[2-[[(R)-(1,4-dimethylpyrazol-3-yl)-(1-methylcyclopentyl)methyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-3-hydroxy-N,N-dimethylpyridine-2-carboxamide |
| Molecular Formula | C24H30N6O4 |
| Purity | ≥95% |
| IUPAC Name | 4-[[2-[[(R)-(1,4-dimethylpyrazol-3-yl)-(1-methylcyclopentyl)methyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-3-hydroxy-N,N-dimethylpyridine-2-carboxamide |
| InChI | InChI=1S/C24H30N6O4/c1-13-12-30(5)28-15(13)22(24(2)9-6-7-10-24)27-17-16(20(32)21(17)33)26-14-8-11-25-18(19(14)31)23(34)29(3)4/h8,11-12,22,27,31H,6-7,9-10H2,1-5H3,(H,25,26)/t22-/m0/s1 |
| InChIKey | WZBSYWCLIMRAHO-QFIPXVFZSA-N |
| SMILES | CC1=CN(N=C1[C@@H](C2(CCCC2)C)NC3=C(C(=O)C3=O)NC4=C(C(=NC=C4)C(=O)N(C)C)O)C |
